NCT01097798 (LBB-ALI-01/09) is a Phase 3 clinical trial of Aliviador in Contusions, sponsored by Laboratorio Brasileiro de Biologia.

Who is sponsoring NCT01097798?

NCT01097798 is sponsored by Laboratorio Brasileiro de Biologia.

What drugs are being tested in NCT01097798?

Interventions in NCT01097798: Aliviador, Gelol.

What condition does NCT01097798 study?

NCT01097798 studies Contusions, Sprains, Trauma, Muscle Injury, Myalgia, Myofascial Pain, Tendinitis.

Is NCT01097798 still recruiting?

NCT01097798 is currently status unknown. Last updated 15 April 2010.

Last reviewed 2010-04-15 · How we verify

NCT01097798: LBB-ALI-01/09

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety Aliviador Compared to Gelol in the Relief in Patients With Contusons, Sprains,Trauma and Muscle Injury.

Status unknown Phase 3 Last updated 15 April 2010

What this trial tests

Phase 3 trial testing Aliviador in Contusions in 120 participants. Status unknown.

Timeline

1 June 2010

Primary endpoint
1 August 2010

1 August 2010

Quick facts

Lead sponsor	Laboratorio Brasileiro de Biologia
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	120
Start date	1 June 2010
Primary completion	1 August 2010
Estimated completion	1 August 2010
Sites	3 locations across Brazil

Drugs / interventions tested

Aliviador — full drug profile →
Gelol — full drug profile →

Conditions studied

Contusions — all drugs for Contusions →
Sprains — all drugs for Sprains →
Trauma — all drugs for Trauma →
Muscle Injury — all drugs for Muscle Injury →

Sponsor

Laboratorio Brasileiro de Biologia — full company profile →

Who can join

12 and older, any sex, with Contusions or Sprains. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the efficacy in reducing signs and symptoms Aliviador compared to Gelol.
Time frame: two days
To evaluate the efficacy in reducing signs and symptoms Aliviador compared to Gelol in patients with contusions, sprains, muscle injury and trauma, starting less than 24 hours or patients with muscle pain, myofascial pain and tendinitis.

Sponsor's own description

Multicenter, randomized, double-blind trial, to evaluate the efficacy and safety Aliviador compared to Gelol in the relief of signs and symptoms in patients with contusions, sprains, trauma and muscle injury start with less than 24 hours or patients of myalgia, myofascial pain and tendinitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01097798 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Laboratorio Brasileiro de Biologia
Last refreshed: 15 April 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01097798.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing